ResearcherCedars-Sinai Medical CenterNo recent work listed

Camille Ng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110943293. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper

Papers 1

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7039 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Veronica Placencio-Hickok · 1 shared paper, 2022 · strength 0.16
- Paper Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2022.7039 ↗
Andrew Eugene Hendifar · 1 shared paper, 2022 · strength 0.16
- Paper Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2022.7039 ↗
Natalie Moshayedi · 1 shared paper, 2022 · strength 0.16
- Paper Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2022.7039 ↗
Jun Gong · 1 shared paper, 2022 · strength 0.16
- Paper Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2022.7039 ↗
Arsen Osipov · 1 shared paper, 2022 · strength 0.16
- Paper Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2022.7039 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.